Five presentations at the ACR Convergence 2021 virtual meeting covered results from the phase 3b/4 postmarketing safety study, which was mandated by the US FDA and carried out between 2014 and 2020.

ACR Convergence 2021; 3–9 November (abstract L16) ACR Convergence 2021; 3–9 November (abstract L04)

Deucravacitinib, a novel selective tyrosine kinase 2 inhibitor, may be a promising treatment option for patients with psoriatic arthritis, suggest phase 2 data presented in a poster at the ACR Convergence 2020 virtual meeting.

ACR Convergence 2021; 3–9 November

ACR Convergence 2021; 3–9 November (abstract 1448) ACR Convergence 2021; 3–9 November (abstract 0815)

The study, which was reported at the ACR Convergence 2021 virtual meeting and published in The Lancet Rheumatology , included 1202 patients with one of these conditions who developed COVID-19 between March 2020 and April 2021.

ACR Convergence 2021; 3–9 November

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

Patients with rheumatic diseases taking biologic therapy were more likely to shield during the first 6 months of the COVID-19 pandemic than those taking other drug types, shows research reported at the ACR Convergence 2020 virtual meeting.

The JAK inhibitor tofacitinib is a promising treatment option for people with ankylosing spondylitis, suggest phase 3 trial findings presented at the ACR Convergence 2020 virtual meeting.

Integration of clinical and protein biomarker data using a machine-learning approach may help to distinguish patients with psoriatic arthritis from those with psoriasis, suggests research presented at the ACR Convergence 2020 virtual meeting.

The incidence of serious adverse events was comparable, at 5.3% and 10.7%, respectively, as was the incidence of infection, at a corresponding 35.5% and 39.3%. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group ACR Convergence virtual meeting; 5–9 November 2020

(9:05) Peter Taylor_081120 medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group ACR Convergence virtual meeting; 5–9 November 2020

Presenting the findings at the ACR Convergence 2020 virtual meeting, Anna Moltó (Cochin Hospital, Paris, France) explained that recommendations for a T2T strategy in patients with axSpA are available, but that they are poorly implemented in clinical practice.

There were no serious adverse events in the secukinumab group, and two in the placebo arm. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group ACR Convergence virtual meeting; 5–9 November 2020

However, secukinumab was not significantly better than placebo for the primary endpoint of Achilles tendon enthesitis resolution at week 24, reported Frank Behrens (Goethe University, Frankfurt, Germany) in a poster presentation at the ACR Convergence 2020 virtual meeting.

The rates, as presented at the ACR Convergence 2020 virtual meeting, were 61.0% versus 51.5% for ACR20, 43.0% versus 32.6% for ACR50, 64.0% versus 37.6% for PASI90, and 53.7% versus 43.9% for HAQ-DI (≥0.35 points).

The rate of serious adverse events was 2.4% and there were no deaths. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group ACR Convergence virtual meeting; 5–9 November 2020

The autotaxin inhibitor ziritaxestat may improve skin fibrosis in patients with early diffuse cutaneous systemic sclerosis, show data from the phase 2a NOVESA study presented at the ACR Convergence 2020 virtual meeting.

ACR Convergence virtual meeting; 5–9 November 2020 Arthritis Care Res 2020; DOI:10.1002/acr.24487